CYBERDYNE (7779) AI Stock Analysis

• Market Cap: ¥57.85B
• Dividend Yield: N/A
• Average Volume (3M): 724.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: -4.30%
• EPS Growth: 82.87%
• Country: JP
• Employees: 227
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.86
• Shares Outstanding: 137,445,820
• 10 Day Avg. Volume: 764,380
• 30 Day Avg. Volume: 724,970
• PEG Ratio: 1.05
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 8.43
• P/FCF Ratio: -50.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥259.00
• Price Target Upside: 19.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: ¥277.00 ▲(28.24% Upside)

The score is held back primarily by poor financial performance (losses, sharp revenue decline, and negative free cash flow) and weak valuation support (negative P/E, no dividend yield provided). Strong technical momentum and an uptrend improve the score, but overbought signals add risk.

Positive Factors

Proprietary HAL platform

A dedicated, proprietary exoskeleton platform provides a durable competitive moat: specialized tech and clinical use create high switching costs, enable equipment leasing and service revenue, and support long-term adoption by hospitals and rehab centers as a core medical device.

Low financial leverage

Minimal leverage gives CYBERDYNE structural financial flexibility: the low debt burden reduces solvency risk, enables continued R&D and commercialization spending during downturns, and preserves the capacity to raise targeted capital without immediate distress.

High gross profit margin

A >50% gross margin indicates strong unit economics and pricing power at the product level: if sales normalize, these margins can support operating leverage, fund service networks and upgrades, and make long-term profitability achievable with scale.

Negative Factors

Sharp revenue decline

A near-60% trailing revenue decline is a structural concern: reduced scale weakens network effects, lowers install base for recurring service income, erodes bargaining with distributors, and makes it harder to absorb fixed R&D and support costs over the medium term.

Persistent unprofitability

Ongoing negative EBIT and net margins constrain retained earnings and reinvestment ability: sustained losses limit capacity to scale commercialization, deter partners, and increase reliance on external funding, raising execution risk for long-term growth plans.

Weak cash flow generation

Persistent negative free cash flow undermines operational resilience: weak cash generation forces reliance on financing, hampers maintenance and service investments critical for medical devices, and increases vulnerability to funding shocks over the next several quarters.

CYBERDYNE Business Overview & Revenue Model

Company Description

CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains equipment and systems for medical and warfare in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; and Acoustic X, a high speed light pulse LED array light source that enables real time photoacoustic imaging. It also provides Cybernics Treatment, a treatment that uses HAL to enhance/regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; HAL FIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes' brain-nerve functions; and Neuro HALFIT for enhancement of physical functions. In addition, the company is involved in the provision of rescue supports in disaster sites, and heavy labor supports for factories and plants; and entertainment business. The company was incorporated in 2004 and is headquartered in Tsukuba, Japan.

How the Company Makes Money

CYBERDYNE generates revenue through multiple channels, including the sale of its robotic products such as the HAL exoskeleton, which is marketed to hospitals and rehabilitation centers. The company also earns income from leasing its robotic systems and providing maintenance and support services. Additionally, CYBERDYNE has formed strategic partnerships with healthcare providers and research institutions, which help to expand its market reach and promote the adoption of its technologies. Grants and funding for research projects further contribute to its revenue streams, particularly in the development of new applications and enhancements of existing products.

CYBERDYNE Financial Statement Overview

Summary

Weak profitability and cash generation: negative net income and EBIT margins alongside a 59.1% TTM revenue decline and negative free cash flow. Balance sheet risk is lower due to minimal leverage (debt-to-equity 0.01), but negative ROE signals poor returns on shareholder capital.

Income Statement

CYBERDYNE's income statement reveals significant challenges, with negative net income and EBIT margins indicating ongoing profitability issues. The TTM data shows a sharp revenue decline of 59.1%, highlighting a concerning trend. Despite a reasonable gross profit margin of 53.4%, the company struggles with negative net profit and EBIT margins, reflecting operational inefficiencies and cost management issues.

Balance Sheet

The balance sheet presents a stable financial position with a low debt-to-equity ratio of 0.01, suggesting minimal leverage and financial risk. However, the negative return on equity indicates that the company is not generating sufficient returns on shareholder investments. The equity ratio remains strong, showcasing a solid asset base relative to equity.

Cash Flow

CYBERDYNE's cash flow statement highlights significant challenges, with negative free cash flow and operating cash flow coverage ratios. The TTM free cash flow growth rate is negative, indicating cash flow management issues. Despite a high free cash flow to net income ratio, the overall cash flow situation remains weak, reflecting potential liquidity concerns.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.20B	4.38B	4.35B	3.29B	2.15B	1.88B
Gross Profit	2.22B	2.37B	2.39B	1.79B	1.28B	1.30B
EBITDA	766.00M	16.00M	-2.00M	873.00M	116.00M	892.00M
Net Income	-201.00M	-577.00M	-1.48B	-298.00M	-498.00M	-59.00M
Balance Sheet
Total Assets	48.91B	48.55B	50.00B	50.19B	48.12B	47.81B
Cash, Cash Equivalents and Short-Term Investments	15.08B	14.86B	16.66B	17.31B	5.68B	6.70B
Total Debt	442.00M	434.00M	632.00M	669.00M	575.00M	421.00M
Total Liabilities	9.30B	8.95B	9.52B	8.20B	4.33B	3.55B
Stockholders Equity	39.60B	39.58B	40.75B	42.10B	43.41B	43.78B
Cash Flow
Free Cash Flow	-118.00M	-735.00M	-1.07B	-652.00M	-1.85B	-620.00M
Operating Cash Flow	4.00M	-430.00M	-850.00M	-143.00M	-775.00M	-215.00M
Investing Cash Flow	322.00M	2.33B	-2.08B	2.17B	-2.79B	-244.00M
Financing Cash Flow	-218.00M	-216.00M	160.00M	14.00M	617.00M	1.30B

CYBERDYNE Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 216.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7779, the sentiment is Positive. The current price of 216 is below the 20-day moving average (MA) of 240.10, above the 50-day MA of 206.84, and above the 200-day MA of 188.26, indicating a bullish trend. The MACD of 18.52 indicates Negative momentum. The RSI at 68.59 is Neutral, neither overbought nor oversold. The STOCH value of 52.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7779.

CYBERDYNE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
5187	78 Outperform	¥10.24B	12.56	―	3.52%	4.97%	-10.07%
7963	74 Outperform	¥9.35B	12.09	―	1.89%	9.47%	37.35%
6523	68 Neutral	¥137.37B	23.49	4.32%	3.73%	0.04%	―
6849	68 Neutral	¥285.97B	15.45	―	1.92%	4.31%	96.31%
7600	58 Neutral	¥12.80B	-12.14	―	3.12%	3.59%	-163.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7779	49 Neutral	¥57.85B	-286.37	-0.46%	―	-4.30%	82.87%

CYBERDYNE Corporate Events

CYBERDYNE Selected for UNIDO’s Green Industrial Recovery Project in Ukraine

CYBERDYNE Inc. has been selected for the United Nations Industrial Development Organization’s ‘Green Industrial Recovery Project for Ukraine,’ funded by Japan’s Ministry of Economy, Trade and Industry. The project aims to support Ukraine’s green industrial recovery through technology transfer and innovation, with CYBERDYNE conducting a feasibility study to establish innovation bases in Ukraine utilizing its Cybernics technology. The impact on CYBERDYNE’s financial results is expected to be minor, with the consignment fee recorded as ‘Other Income’ during the contract period.

The most recent analyst rating on (JP:7779) stock is a Hold with a Yen195.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.

CYBERDYNE Issues Correction on Financial Claims Announcement

CYBERDYNE Inc. has issued a correction to its previous announcement regarding the risk of irrecoverability or delayed collection of claims. The correction involves a change in the percentage of consolidated net assets affected by a loan to LeyLine, which has been adjusted from 0.01% to 0.64%. This correction may impact stakeholders’ perception of the company’s financial stability.

The most recent analyst rating on (JP:7779) stock is a Hold with a Yen178.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.

CYBERDYNE Faces Potential Loan Recovery Challenges with Former Subsidiary

CYBERDYNE Inc. has announced a potential risk regarding the irrecoverability or delayed collection of a loan to LeyLine GmbH, a former subsidiary. The company has recorded an allowance for doubtful accounts amounting to ¥252 million due to delays in repayment. CYBERDYNE plans to continue collection efforts and may consider legal actions to protect its receivables.

The most recent analyst rating on (JP:7779) stock is a Hold with a Yen178.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.

CYBERDYNE Reports Improved Profit Amid Revenue Decline

CYBERDYNE, INC. reported its consolidated financial results for the six months ending September 30, 2025, showing a decrease in revenue by 8.4% compared to the previous year. Despite the revenue drop, the company managed to achieve a profit before tax of 297 million yen, indicating a positive turnaround from the previous year’s loss. The company did not provide a forecast for the fiscal year ending March 31, 2026, due to uncertainties in the innovative market it operates in.

The most recent analyst rating on (JP:7779) stock is a Hold with a Yen178.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.